Episode Summary
In this episode of 340B Pulse, Muhammad Atif speaks with Greg Doggett, an attorney and longtime 340B policy and compliance leader now with Powers, Pyles, Sutter & Verville in Washington, D.C. Greg spent roughly fifteen years at 340B Health (formerly Safety Net Hospitals for Pharmaceutical Access), later worked on pharmaceutical pricing and 340B policy at Walgreens, and now advises hospitals and grantees on compliance, regulatory issues, and advocacy.
The central argument is that 340B is not only contested; it is more structurally complex than at any point in the program's recent history. Court cases, manufacturer-specific policies, Medicaid managed care fragmentation, and HRSA's push toward rebate-based models are reshaping how duplicate discounts are prevented, how data moves between stakeholders, and how stable the program feels for operators planning twelve to twenty-four months out.
Greg defines duplicate discounts as instances where a manufacturer provides both a 340B discount and a rebate on the same claim, with Medicaid duplicate discounts as the most familiar variant. Fee-for-service Medicaid has a federal prevention mechanism through the Medicaid exclusion file; Medicaid managed care does not, leaving states and plans to implement varied approaches without clear HRSA guidance. Manufacturers argue they lack claim-level visibility to validate claims and prevent duplicate payments at scale. Covered entities counter that rebate models would upend upfront discount mechanics, strain cash flow, and divert resources from patient services.
The conversation covers HRSA's blocked 2025 rebate pilot, what that litigation signals about regulatory limits, the all-hands-on-deck operational burden inside health systems if rebate conversion expands, why litigation is outpacing rulemaking as a policy driver, and how vendor platforms (Beacon, Truzo, Kalderas, Secured Site Solutions) are becoming infrastructure for data validation. Greg proposes a federal neutral 340B clearinghouse as potential common ground, discusses AI's emerging role in compliance operations, and flags provider concerns about submitting claims and encounter data to manufacturers without compensation or confidentiality guarantees.
Rapid-fire answers underscore Greg's view that duplicate discounts are not unsolvable under the current model, rebate conversion is not inevitable, Medicaid managed care makes national standards difficult, operational burden is underestimated, some common ground exists, and lawsuits, not HRSA rules or new legislation, are most likely to shape the near-term future.
Show Notes
- Greg's career path through 340B Health, Walgreens health policy, and Powers law practice.
- Why 340B complexity today exceeds prior contested eras despite longstanding manufacturer-provider tension.
- Duplicate discount definition, Medicaid FFS vs managed care prevention gaps, and the Medicaid exclusion file.
- Manufacturer arguments for rebate-based models: claim-level data needs and duplicate discount exposure.
- HRSA's 2025 rebate pilot, court injunction, and limits of agency rulemaking without congressional reset.
- Covered-entity concerns: upfront payment, rebate reconciliation, cash flow, and service-line tradeoffs.
- Cross-functional operational burden inside health systems (340B ops, IT, finance, HR, leadership).
- Medicaid managed care modifier requirements vs retrospective 340B inventory workflows.
- Litigation's impact on program predictability and congressional hesitation to legislate amid active cases.
- HRSA regulatory authority limits, contract pharmacy guidance litigation, and stakeholder disagreement persistence.
- Vendor portal roles in duplicate discount detection and contract pharmacy access conditions.
- Neutral federal clearinghouse as a compromise framework for data governance.
- AI use in duplicate discount detection and compliance labor reallocation; data privacy and manufacturer data requests.
- Rapid-fire policy outlook on rebates, national standards, and lawsuit-driven change.